Learn how QSP and PBPK modeling work together to support oncology drug development decisions, from dose justification to patient population identification.
About this webinar
Mechanistic modeling approaches are transforming how oncology compounds reach patients. This webinar explores how quantitative systems pharmacology (QSP) and physiologically based pharmacokinetic (PBPK) modeling, when used in combination, provide a powerful framework for informing critical decisions in drug development.
Using tipifarnib and alpelisib combination therapy for head and neck squamous cell carcinoma (HNSCC) as a case study, the session will walk through how these tools support dose justification, patient stratification by genotype, and assessment of drug–drug interactions and organ impairment.
What you will learn
- How QSP models can characterize tumor response across distinct patient genotypes to identify which populations are most likely to benefit from treatment and support dose justification
- How a logic-gated, mechanistic model is built, calibrated, and translated from preclinical data to clinical predictions
- How PBPK modeling supports drug–drug interaction (DDI) assessment, and organ impairment evaluation for oncology compounds
- How combining QSP and PBPK approaches within a single development program creates a stronger, more integrated evidence package for regulatory and clinical decisions
- Practical lessons from the tipifarnib program that apply across oncology drug development
Who should watch
- QSP & systems pharmacologists
- Clinical pharmacologists
- Pharmacokineticists & DMPK scientists
- Oncology drug developers
- Translational researchers
